First Quarter 2020 12 May 2020 Dr. Andreas Eckert CEO 1 Globally - PowerPoint PPT Presentation

First Quarter 2020 12 May 2020 Dr. Andreas Eckert CEO 1

Globally Globa lly Pos Positi itione oned Niche Play Niche Player er in I in Iso sotope tope Market Market ISOTOPE PRODUCTS MEDICAL * (industrial components) Radiation Therapy Products Services Radiopharma Trade Lab Devices *Since January 1, 2020, Eckert & Ziegler has consolidated its Disposa l Radiation Therapy and Engineering Radiopharma segments under the new name MEDICAL 21 Mio. EUR 23 Mio. EUR 46%* 52%* *figures without Holding segment 45 Mio. EUR Revenues in Q1-2020 Slides only for illustration – the spoken word shall be binding 2

>800 >800 Employ Employee ees (Head (Headco coun unts ts) ) 18 18 Site Sites s Wo World rldwide wide Results Q1-2020 (Mio. EUR) Revenues 44,5 Net Income 5,1 8% 2% 49% 41% EUROPE AMERICA ASIA MIDDLE EAST & AFRICA 3 Slides only for illustration – the spoken word shall be binding

Reven Rev enue ue Gro Growth wth Q1-2020 Total Revenues 44,5 mm. EUR Q1-2019 Total Revenues 43,3 mm. EUR Growth over last year: +2% 30,00 25,00 20,00 In mm. EUR 15,00 10,00 5,00 - Isotope Products Medical Q1-2019 27,0 16,4 Q1-2020 23,2 20,6 incl. discontinued and continued operations Slides only for illustration – the spoken word shall be binding 4

Isot Isotop ope Pro e Produ duct cts: s: Rev Reven enue ue Gro Growth wth Q1 Q1-20 2020 20, , in mm. in mm. EUR EUR 28 27 26 25 - 4,5 24 27,0 23 + 0,8 22 23,2 21 20 Revenues Q1-2019 Organic Growtth Exchange Rate Effects Revenues Q1-2020 Slides only for illustration – the spoken word shall be binding 5

Med Medical: ical: Rev Reven enue ue Gro Growth wth Q1 Q1-20 2020 20, , in mm. in mm. EUR EUR 21 + 0,4 19 + 3,8 17 15 13 20,6 11 16,4 9 7 5 Revenues Q1-2019 Organic Growtth Exchange Rate Effects Revenues Q1-2020 Slides only for illustration – the spoken word shall be binding 6

Net Net Rev Revenu enues es Growth Growth all Segmen all Segments ts in in Q1 Q1-202 2020, 0, in mm. in mm. EUR EUR 45 + 4,4 - 3,7 40 35 30 25 44,5 43,3 20 15 10 5 0 Revenues Q1-2019 Isotope Products Medical Revenues Q1-2020 Slides only for illustration – the spoken word shall be binding 7

Ne Net Inc t Incom ome e – Dist Distrib ribut ution ion an and Gr d Growth wth Q1-2020 Q1 2020 Slides only for illustration – the spoken word shall be binding 8

Net Net I Inc ncome ome Gro Growth wth Q1-2020 Total Net Income 5,1 mm. EUR Q1-2019 Total Net Income 5,8 mm. EUR Lost over last year: -13% 3,5 3,0 2,5 In mm. EUR 2,0 1,5 1,0 0,5 0,0 Isotope Products Medical Q1-2019 3,0 2,7 Q1-2020 1,4 3,5 Slides only for illustration – the spoken word shall be binding 9

Net Net I Inc ncome ome Gro Growth wth all all Seg Segmen ments ts in Q1 in Q1-20 2020 20, , in mm. in mm. EUR EUR 7,0 6,0 - 1,6 + 0,0 5,0 + 0,8 4,0 3,0 5,8 5,1 2,0 1,0 0,0 Net income Q1-2019 Isotope Products Medical Holding Net income Q1-2020 Slides only for illustration – the spoken word shall be binding 10

Isot Isotop ope Pro e Produ duct cts: s: Net Net Inco Income me Gro Growth wth Q1 Q1-20 2020 20, , in mm. in mm. EUR EUR 3 3 - 1,1 2 3,0 2 - 1,0 + 0,5 1 1,4 1 0 Net income Q1-2019 Organic Growth Exchange Rate Effects Tax/Interest/Minorities Net income Q1-2020 Slides only for illustration – the spoken word shall be binding 11

Med Medical: ical: Net Net Inco Income me Gro Growth wth Q1-20 Q1 2020 20, , in in mm. mm. EUR EUR 7 6 + 2,1 5 + 4,2 + 0,5 4 - 0,9 3 2 + 3,5 + 2,7 1 0 Net income Q1-2019 Revenues COGS Sales and Administrative Exchange Net income Q1-2020 Cost Rate/Interesrt/Tax Slides only for illustration – the spoken word shall be binding 12

Cas Cashflo hflow and w and Balan Balance ce She Sheet et Q1 Q1-2020 2020 Slides only for illustration – the spoken word shall be binding 13

Balan Balance ce She Sheet et as as of of 31 31/03/2 /03/202 020, 0, in in mm. mm. EUR EUR Cash 81 Equity 144 Recievables 29 Minority Interests 1 Inventory 33 IFRS 16 Leasing 19 Intangible Assets 52 Accruals/Provisions 68 Fixed Assets 40 Other Short Term Payables 37 Others 22 Other Long Term Payables 7 Total Activ 275 Total Passiv 275 • Cash at Hand 81 mm. EUR • Debt Free • Equity Ratio 53% (+ 2% over Dec. 2019) Slides only for illustration – the spoken word shall be binding 14

Net Net Liquidity Liquidity Q1 Q1-20 2020 20, , in in mm. mm. EUR EUR +10 mm EUR Share Buy-Back 80 80 70 70 60 60 50 50 In mm. EUR 40 40 30 30 20 20 10 10 0 0 2014 2015 2016 2017 2018 2019 Q1-2020 Zahlungsmittel 22 31 37 58 54 79 81 Darlehen 19 16 12 2 0 0 0 Nettoliquidität 3 15 25 56 54 79 81 Folie nur zur Illustration – es gilt das gesprochene Wort 15

Cas Cashflow hflow Q1 Q1-20 2020 20, , in in mm. mm. EUR EUR EBITDA: 11,3 mm. EUR 90,0 0,1 -1,6 4,7 -1,2 80,0 70,0 60,0 80,8 78,9 50,0 40,0 30,0 Liquidity 31.12.19 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Liquidity 31.03.20 Slides only for illustration – the spoken word shall be binding 16

Stock Sto ck an and Dividen d Dividend in E in EUR/St UR/Stoc ock 200 1,70 180 160 1,50 140 1,30 120 1,7 100 1,10 80 0,90 60 1,2 40 0,70 0,8 20 0,66 0,60 0,60 0,60 0,50 0 2014 2015 2016 2017 2018 2019 2020 Dividend in EUR/Share EUR/Aktie Slides only for illustration – the spoken word shall be binding 17

Cor Coron ona Upd a Updat ate Lo Look oking ing Ah Ahea ead Exp Expec ecta tation tions s for for 2020 2020 Folie nur zur Illustration – es gilt das gesprochene Wort 18

Key Key Elemen Elements ts of of Guida Guidanc nce 20 2020 20 (EBIT) (EBIT) in Mio. EUR Slides only for illustration – the spoken word shall be binding 19

Exp Expan ansion sion Str Strat ateg egy Galli Gallium um-68 68/ / The Thera rano nost stics ics Additional Isotopes (e.g. Lu-177) Treatment EZAG Diagnosis today Additional indications Slides only for illustration – the spoken word shall be binding 20

Exp Expan ansion sion Str Strat ateg egy Yt Yttr trium ium-90 90/ / Rad Radioemb ioembolisat olisation ion Geographic Expansion Boston (US) site ROW including Chengdu (PRC) China site EZAG Europe today SIRTEX Customer Europe Base Slides only for illustration – the spoken word shall be binding 21

Sho Short rt/ Medium / Medium Ter Term m Goa Goals ls for for Rad Radioph iophar arma ma Ingr Ingred edient ients Building Worldwide Supply Chains / Global Network Status as of March 2020 Status as of March 2020 Yttrium-90 Lutetium-177 • New production site in • Validated technology Boston initiated • Value chain has been completed • Production site in Chengdu • Five reactors qualified Chengdu on schedule thereof two non-European sites • Numerous alliances in the • First deliveries to customers pipeline

Fina Financ ncial ial Calen Calenda dar r / I / IR Con R Conta tact ct 12.05.2020 Quarterly Report I IR Contact 10.06.2020 Annual General Meeting (virtual) Eckert & Ziegler AG 13.08.2020 Quarterly Report II Karolin Riehle 10.11.2020 Quarterly Report III Investor Relations & PR (subject to changes) Robert-Rössle-Str. 10 D-13125 Berlin Tel. +49 30 94 10 84-138 ISIN DE0005659700 Fax +49 30 94 10 84-112 Reuters EUZ.DE karolin.riehle@ezag.de www.ezag.de Folie nur zur Illustration – es gilt das gesprochene Wort 23